Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF Switch in HIV/HBV Co-infected Patients with Renal Dysfunction
NCT03115736Phase 2Completed
- Sponsor
- Insel Gruppe
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) and hepatitis B (HBV), sponsored by Insel Gruppe. Primary endpoints: Change in renal function at 48 weeks and HBV suppression at 48 weeks. Started May 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03115736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115736.